About us

Isofol Medical AB (publ) works to improve the quality of life and prognosis for patients with severe forms of cancer. The company’s drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world’s third most common cancer, where the medical need for better treatments is truly urgent.

Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

Colorectal cancer (CRC) is the third most common form of cancer worldwide and there is a very high need for more effective drugs to treat this disease.

Last updated 01-30-2025

Scroll to Top